A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Clinical trial NCT01998841 · COMPLETED

Trial details

NCT number: NCT01998841
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alzheimer's Disease

Start date: 2013-12-20
Primary completion: 2022-03-22
Enrollment: 252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.